TENORMIN (atenolol) by AstraZeneca is clinical pharmacology atenolol is a beta 1 -selective (cardioselective) beta-adrenergic receptor blocking agent without membrane stabilizing or intrinsic sympathomimetic (partial agonist) activities. First approved in 1989.
Drug data last refreshed 3d ago
TENORMIN (atenolol) is a beta-1-selective beta-adrenergic receptor blocking agent used to treat hypertension, angina, coronary artery disease, and left ventricular hypertrophy. It works by reducing heart rate and blood pressure through selective inhibition of beta-1 receptors in the heart, with minimal hepatic metabolism and primarily renal elimination. The drug demonstrates rapid oral absorption with peak effects within 2-4 hours and sustained 24-hour efficacy.
Mature product approaching loss of exclusivity signals defensive positioning; commercial team focus shifts to retention and cost management rather than growth.
CLINICAL PHARMACOLOGY Atenolol is a beta 1 -selective (cardioselective) beta-adrenergic receptor blocking agent without membrane stabilizing or intrinsic sympathomimetic (partial agonist) activities. This preferential effect is not absolute, however, and at higher doses, atenolol inhibits beta 2…
Worked on TENORMIN at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension
Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure
Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWork on TENORMIN involves defensive commercial strategies, managed-care negotiations, and generic transition planning rather than market expansion. Career progression may be limited as the product enters LOE; roles emphasize retention, compliance, and internal re-deployment opportunities.
51 open roles linked to this drug